Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol
I’m an HCP I’m a Patient

Cost and coverage don’t have to stand in the way of choosing Xopenex HFA® for your patients.

If cost or access has been a barrier to prescribing Xopenex HFA, it may be time to reconsider. Broad coverage is now available across many commercial and public plans.

A hand holding the Xopenex HFA Savings Card

Download Card

Affordable Options

$25* for eligible commercially insured patients.

$40* for eligible Direct Access patients.

Download Card from Consumer Site
The Xopenex HFA Savings Card, showing $25 for commercially insured patients and $40 for Direct Access patients

*Per fill. Not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any state or federally funded program, including Medicare, Medigap, or Medicaid, or where prohibited, taxed or otherwise restricted by law. Eligibility requirements and terms and conditions apply. See Terms and Conditions for full details.

  • Favorable Insurance Coverage

  • Low Cost Burden for Patients & Copay Card

  • Wide Availability at Pharmacies Nationwide

This makes Xopenex HFA an affordable option for appropriate patients who:

  • May have concerns about costs or coverage under their commercial plan.
  • Depend on Medicaid state drug plans for their prescription coverage.
  • Depend on Medicare Part D for their prescription coverage.

Important Safety Information

Indication

Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

Important Safety Information

Contraindication

Xopenex HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of Xopenex HFA Inhalation Aerosol.

Warnings and Precautions

  • Xopenex HFA and other β-agonists can cause paradoxical bronchospasm, which may be life threatening. Discontinue Xopenex HFA immediately and treat with alternative therapy.
  • Need for more doses of Xopenex HFA than usual may be a sign of deterioration of asthma and requires reevaluation of treatment.
  • Xopenex HFA is not a substitute for corticosteroids.
  • Cardiovascular effects may occur. Consider discontinuation of Xopenex HFA if these effects occur. Use with caution in patients with underlying cardiovascular disorders.
  • Excessive use may be fatal. Do not exceed recommended dose.
  • Immediate hypersensitivity reactions may occur. Discontinue Xopenex HFA immediately.
  • Hypokalemia and changes in blood glucose may occur.

Adverse Reactions

  • In patients aged 4 to 11 years, the most common adverse events (occurring in ≥2% of patients receiving Xopenex HFA and more frequently than patients receiving placebo) were vomiting, accidental injury, pharyngitis, and bronchitis.
  • In patients 12 years and older, the most common adverse events (occurring in ≥2% of patients receiving Xopenex HFA and more frequently than patients receiving placebo) were asthma, pharyngitis, rhinitis, pain, and dizziness.

For more information about Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals at +1 866‑587‑4617 or at drugsafety@lupin.com or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

References

1. Xopenex HFA® [Prescribing Information]. Lupin Pharmaceuticals, Inc.: Baltimore, MD; July 2023.

2. Lötvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 2001 Nov;108(5):726-31. doi: 10.1067/mai.2001.119152.

3. Data on file. CSR 051-354. Sunovion Pharmaceuticals, Inc.